Cibus, Inc.
NASDAQ:CBUSBiotechnology
+$0.04 today
- Market cap
- $104.71M
- Beta
- 1.65
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.16
Volume 0.25M
Average 0.51M
CBUS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Cibus, Inc.NASDAQ: CBUS
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$10.92M, compared with -$39.38M a year earlier. Trailing-twelve-month EBITDA was -$62.31M.
Context
- EBITDA amounted to 2494.3% of revenue in FY2025, down 3175.2 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of -$7.55M (+91.7%) for the fiscal year ending Dec 2026, a step up from the +62.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$10.92M+48.6% QoQ
- Last fiscal yearDec 2025
- -$90.77M+62.4% YoY
- LTMMar 2026
- -$62.31M+76.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +72.3% | +75.6% | +3.3 pp |
| 1 year | +62.4% | +91.7% | +29.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (90.77M) USD
- Year-over-year change
- +62.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (90.77M) | +62.4% |
| FY2024 | 2024-12-31 | (241.64M) | +23.2% |
| FY2023 | 2023-12-31 | (314.59M) | -1968.3% |
| FY2022 | 2022-12-31 | (15.21M) | +40.2% |
| FY2021 | 2021-12-31 | (25.43M) | — |
EBITDA vs competitors
How CBUS compares with its peers on the latest reported figures
- CBUS's LTM Mar 2026 EBITDA of -$62.31M is the 7th highest of the 10 companies compared; the peer median is -$52.24M.
- Its year-over-year change of +76.4% is the 2nd highest of 10, against a peer median of -1.2%.
- EBITDA amounts to 1453.8% of revenue for CBUS, versus a peer median of 1327.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.3M | +203.4% | — | 18.5% | |
| LTM Mar 2026 | -$11.72M | -5.2% | — | 1963.7% | |
| LTM Mar 2026 | -$39.25M | -164.0% | — | — | |
| LTM Mar 2026 | -$46.12M | +63.6% | — | — | |
| LTM Mar 2026 | -$52.24M | -1.2% | — | 1327.8% | |
| LTM Mar 2026 | -$58.88M | -297.6% | — | — | |
CBUSCibus, Inc. | LTM Mar 2026 | -$62.31M | +76.4% | — | 1453.8% |
| LTM Mar 2026 | -$78.19M | +0.2% | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$82.08M | +0.7% | — | — |
| LTM Mar 2026 | -$104.13M | -8.2% | — | — | |
| Peer median (excluding CBUS) | -$52.24M | -1.2% | — | 1327.8% | |
Competitors are the stored peer set for CBUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 25.99M | 157K | 1.82M | 4.26M | 3.64M |
| Cost of Revenue | 28.56M | 1.53M | 395K | 0 | 5.92M |
| Gross Profit | (2.57M) | (1.38M) | 1.42M | 4.26M | (2.28M) |
| Gross Margin | -9.9% | -877.1% | 78.3% | 100.0% | -62.8% |
| Research & Development | 11.34M | 11.55M | 42.37M | 50.43M | 44.2M |
| Selling, General & Admin | 15.38M | 9.44M | 28.91M | 30.8M | 26.91M |
| Operating Expenses | 26.76M | 20.99M | 320.31M | 262.66M | 65.18M |
| Depreciation & Amortization | 2.34M | 1.53M | 4.69M | 6.86M | 5.92M |
| EBITDA | (25.43M) | (15.21M) | (314.59M) | (241.64M) | (90.77M) |
| EBITDA Margin | -97.9% | -9687.9% | -17313.4% | -5669.5% | -2494.3% |
| Operating Income | (29.33M) | (22.37M) | (318.88M) | (258.4M) | (67.46M) |
| Operating Margin | -112.9% | -14248.4% | -17550.0% | -6062.8% | -1853.9% |
| Interest Income | 17K | 60K | 527K | 631K | 438K |
| Interest Expense | 1.43M | 87K | 18.89M | 34.19M | 35.48M |
| Other Income / Expenses | 133K | 5.48M | (18.76M) | (24.29M) | (64.71M) |
| Income Before Tax | (29.2M) | (16.89M) | (337.64M) | (282.68M) | (132.17M) |
| Pre-Tax Margin | -112.4% | -10758.6% | -18582.4% | -6632.7% | -3632.1% |
| Income Tax Expense | 0 | 0 | (4K) | 29K | 29K |
| Net Income | (29.2M) | (16.89M) | (267.63M) | (251.39M) | (127.09M) |
| Net Margin | -112.4% | -10758.6% | -14729.1% | -5898.4% | -3492.3% |
| EPS (Basic) | (0.05) | (0.03) | (25.95) | (10.83) | (2.78) |
| EPS (Diluted) | (0.05) | (0.03) | (25.95) | (10.83) | (2.78) |
| Weighted Avg Shares | 578.47M | 578.47M | 10.31M | 23.22M | 457.57M |
| Weighted Avg Shares (Diluted) | 578.47M | 578.47M | 10.31M | 23.22M | 457.57M |
Cibus, Inc.
NASDAQ:CBUS
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.